DIA: Driving Insights to Action

WHO 2030 Framework for Efficient, Effective Regulation

Dr. Petra Doerr, Deputy Executive Director of Swissmedic, and Dr. Murray Lumpkin, Deputy Director of Regulatory Affairs and Lead for Global Regulatory Systems Initiatives for the Bill and Melinda Gates Foundation, explain the World Health Organization’s Essential Medicines and Health Products Strategic Framework for 2016 to 2030.

AI: Opportunity for More Informed Drug Development Decisions

Conversations about artificial intelligence in drug discovery and development are shifting from theoretical questions to practical implementation and impact. Detlef Hold, Global Strategy Lead, Knowledge Cycling (Genentech), and panelist for Exploring Use of Artificial Intelligence at DIA Europe 2018, discusses AI and machine learning in the workplace.

Clinical Training Critical in China’s Cancer Fight

Dr. Shun Lu, Director of the Shanghai Lung Cancer Center at Shanghai Jiaotong University in China, discusses the importance of training doctors and nurses for clinical research in China’s fight against cancer and his experience on the Steering Committee for the 10th DIA China Annual Meeting. (Note: You may notice small gaps in audio due to transpacific connection.)

Changing Research in China: From Generics to Innovators

As Director of the Phase 1 Unit of the Clinical Pharmacological Research Center at Peking Union Medical College, Dr. Pei Hu has been a driving force in advancing model-based drug development in China. Dr. Hu discusses recent changes impacting clinical research in China and her service as co-chair of our 10th DIA China Annual Meeting in Beijing.

Running Away from Addiction Has Caught Up with US

The US Centers for Disease Control and Prevention estimates that the annual "economic burden" from prescription opioid abuse–including the costs of healthcare, lost productivity, addiction treatment, and criminal justice–is $78.5B. Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), US National Institutes of Health, discusses opportunities to turn back this tide and previews the Keynote Address she will deliver at our DIA 2018 Global Annual Meeting this June.

Has the Time for Big/Real World Data Finally Arrived?

Dr. Shahid Hanif, Head of Health Data & Outcomes for the Association of the British Pharmaceutical Industry, discusses the IMI Big Data for Better Outcomes initiative in advance of the session Has the Time for Big/Real World Data Finally Arrived? which he will chair at DIA Europe 2018.

Will AI Make Workers More (or Less) Valuable?

Patrick Brady, Vice President for Regulatory Policy & Intelligence at Bayer, discusses the impact of artificial intelligence on clinical and regulatory science professionals. Mr. Brady will moderate the panel discussion Exploring the Use of Artificial Intelligence: Trust in Technology, or Trust in Each Other? at DIA Europe 2018.

PvPI: Technology Meets Opportunity to Improve Safety

Dr. J. Vijay Venkatraman, India Regional Editor for Global Forum and Managing Director & CEO for Oviya MedSafe Private Limited (India), discusses the Pharmacovigilance Guidance Document for Marketing Authorization Holders of Pharmaceutical Products in India, which came into effect January 2018, and the Pharmacovigilance Programme of India (PvPI).

New EU CTR: One Application, One Portal, One Decision

Harmonizing clinical trial assessment and supervision in the EU through the portal and database established by the new EU Clinical Trial Regulation, and maintained by the EMA, is not the only change rippling through clinical trials in Europe, explain Dr. Mireille Muller, Regulatory Policy Director for Novartis A-G in Switzerland; and Dr. Greet Musch, Director-General for Pre-Authorisation at the Federal Agency for Medicines and Healthcare Products of Belgium. Dr. Muller and Dr. Musch will help lead discussions on this topic at DIA Europe 2018.

US Generic Drug Policy: Less Cost, Same Impact

Maryll Toufanian, JD, Acting Director, US FDA Office of Generic Drug Policy, discusses the US FDA’s Drug Competition Action Plan, why US consumers can feel safe taking generic drugs, and how generic drugs can help reduce costs for healthcare patients and systems. Learn more at our Complex Drug-Device Generic Combination Products conference.